CliffBio
small molecule

CITALOPRAM HYDROBROMIDE

CITALOPRAM HYDROBROMIDE

Loss of exclusivity—loss of exclusivity
CompanyAlmatica Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameCITALOPRAM HYDROBROMIDE
Active ingredientCITALOPRAM HYDROBROMIDE
StrengthEQ 30MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2022
Marketing statusRX

More from Almatica Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CITALOPRAM HYDROBROMIDE patent cliff — loss of exclusivity — | CliffBio